For nearly two decades, the Recap Allicense Conference has provided a unique forum for dealmaking, licensing and business development professionals to discuss and debate dealmaking trends. Recap became a part of Thomson Reuters, the leading provider of intelligence solutions for Life Sciences, in 2013. Together, the integrated Thomson Reuters & Recap offering provides customers with a single source of insight allowing them to quickly and reliably ensure that they are finding the right partnership opportunities; and are structuring deal terms that maximize the value those partnerships contribute to their business.
Allicense 2016 will bring together MVPs from the Pharma, Biotech and Financial communities to tackle today’s most relevant issues and shape the future of dealmaking in the BioPharma industry. Allicense is the only event where 200+qualified dealmakers focus exclusively on key issues facing the industry.
• Over 40% attendees are SVP level and above
• 200+ Qualified Deal Markers
• Editorially driven program lead by senior Thomson Reuters Recap Analysts
• Exclusive opportunity to sponsor event at a range of level
"An excellent venue for getting updates on the industry and making important contacts and connections. The topics are always relevant and the panels are filled with industry leaders across the spectrum of biotech and pharma.
Intellectually and professionally stimulating, it ranks up there with the top five conferences you’d want to attend."
ALLICENSE: THE THOMSON REUTERS SENIOR DEALMAKERS EVENT AT BIO
Now is a time of great change, to which dealmakers need to be prepared to react and, better, which dealmakers might help to shape. Changes include financial markets, the presidential campaign situation in the US, pricing questions, etc.
Put another way – the pendulum is swinging back. What have we learned so that we can do things differently this time, so that we can keep the innovation engine – and the dealmaking ecosystem – healthy and running smoothly in the downshifting part of the cycle?Together with 200+ dealmakers, we’ll learn how to make better more quantifiable deals.
To accomplish this mission, Thomson Reuters serves as a catalyst for discussion, learning and innovation. Celebrating its 20th year, this year’s forum will examine the many facets of the evolving relationship between biotech, pharma, VCs, academia and payers.
We are pleased to be joining forces with BIO for the first time in 2016! Allicense’s high-level focus on biopharma dealmaking seemed a perfect fit for the BIO International Convention’s educational mission, networking platform and global reach.